Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Several nanoformulated anti-cancer substances are currently commercialized or under development. Pre-clinical and clinical results have revealed better properties, that is, larger efficacy and lower toxicity for these substances than for conventional anti-cancer treatments. Here, we review the development of several of these substances such as Marqibo, Myocet, Doxil, DaunoXome, MM398, MM302, Mepact, Versamune, Thermodox, Depocyt, Livatag, Abraxane, Eligard, Opaxio, Zinostatin Stimalamer (SMANCS), Pegasys and PegIntron, BIND-014, CRLX-101, Oncaspar, Neulasta, Aurimmune, Auroshell, AuNPs, Nanotherm, NanoXray, Magnetosome chains, Kadcyla (T-DM1), Ontak (DAB/IL2), Gendicine and Curcumin. We describe their specific properties, such as their stability, solubility, mean of administration or targeting, distribution, metabolism and toxicity. We discuss their categorization as medical devices or drugs, their fabrication process within a regulatory environment as well as intellectual property and financial aspects that are all essential to enable their industrial development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173 · cited 1×
“Among the critical steps of nanoformulation are: (i), coating, which should be chosen to yield high level of biocompatibility, stability and nanoformulated substance accumulation within tumours, minimization of rapid clearance by the RES following intravenous administration, prolongation of plasma circulation, improve…”
BackgroundAlbumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695 · cited 1×
“The MTD of Abraxane has been shown to be 300 mg/m2, higher than that of 175 mg/m2 observed with free paclitaxel (46, 47).”
BackgroundThe effect of thermotherapy using magnetic nanoparticles on rat malignant glioma
Jordan, A., Scholz, R., Maier-Hauff, K., van Landeghem, F. K. H., Waldoefner, N., Teichgraeber, U., Pinkernelle, J., Bruhn, H., Neumann, F., Thiesen, B., et al. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9059-z · Cited by 459 · cited 1×
“The efficacy of nanoformulated substance needs to be demonstrated pre-clinically, usually on mice or rats, apparently without the requirement of a specific regulatory framework or a minimum efficacy threshold (62, 87, 115).”
BackgroundWerner, M. E., Cummings, N. D., Sethi, M., Wang, E. C., Sukumar, R., Moore, D. T., & Wang, A. Z. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.009 · Cited by 267 · cited 1×
“In 2012, 67 nanodevices and 33 nanotherapeutics were commercialized, 25 nanodevices were under development, and 122 nanotherapeutics were involved in 789 ongoing clinical trials [144].”
BackgroundDiagaradjane, P., Shetty, A., Wang, J. C., Elliott, A. M., Schwartz, J., Shentu, S., Park, H. C., Deorukhkar, A., Stafford, R. J., Cho, S. H., et al. (2008) · Nano Letters · doi:10.1021/nl080496z · Cited by 215 · cited 1×
“the treatment is combined with radiation, antitumor efficacy is enhanced compared with a treatment with radiation alone, (76).”
Background
Cited by
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., & Aldughaim, M. S. (2023) · Polymers · doi:10.3390/polym15071596 · Cited by 914
Recent advancements in liposome technology
Filipczak, N., Pan, J., Yalamarty, S. S. K., & Torchilin, V. P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.022 · Cited by 592
Doxorubicin: nanotechnological overviews from bench to bedside
Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.005 · Cited by 362
Metadata
- Authors
- Alphandéry, E., Grand-Dewyse, P., Lefèvre, R., Mandawala, C., & Durand-Dubief, M.
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-09-24
- Volume
- 15
- Issue
- 10
- Pages
- 1233-1255
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2149144667
- Cited by
- 108
- References
- 6
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.